Run the List – Detailed Summary

Episode: Approach to Prevention in Cardiovascular Disease
Host(s): Walker Redd, Emily Gutowski, Navin Kumar, Joyce Zhou, Blake Smith
Guest: Dr. Greg Katz, Cardiologist (NYU Langone)
Date: February 17, 2025
Theme: A practical, evidence-based approach to cardiovascular disease (CVD) prevention with clinical focus on individualized risk assessment, lifestyle, medication, and emerging therapies.

Overview

This episode presents a practical primer on the modern approach to preventing cardiovascular disease, focusing on both lifestyle and medical interventions. Dr. Greg Katz walks through a detailed case and shares clinician pearls regarding risk calculation, the evolving role of lipid markers, when to use imaging, and bold perspectives on statins, aspirin, GLP-1 agonists, and comprehensive risk management.

Key Discussion Points & Insights

1. Initial Case & Core Approach

[02:08]–[05:25]

• Case: 62-year-old male with diabetes, hypertension, hyperlipidemia, obesity, previous smoker, and family history of early MI.
• Key Point: “This patient is more likely to die of cardiovascular disease than anything else. There are a lot of things we can do to modify his risk.” — Dr. Katz [02:15]
  • Focus: Divide interventions into medical (medications, risk testing) and lifestyle (diet, activity, stress, sleep, social health).
  • Emphasizes listening to the patient’s readiness for medications vs. interest in understanding risk or pursuing lifestyle change.
  • Family history (MI or stroke <60 in a first degree relative) = strong risk factor.

Notable Quote:
“You are coming to medical attention at a really good time. Nothing bad has happened to him yet… we can really do a lot to change his risk.”
— Dr. Katz [03:19]

2. On Risk Calculators in Practice

[05:25]–[08:07]

• Dr. Katz is “so anti risk calculator” for individual decision-making, although they are valuable for population-level estimates.
• Problem: Calculators are overly age-driven; may miss high-risk younger patients and over-treat older adults.
• Clinically: “There’s no number I’m going to see on a risk calculator that’s going to persuade me we shouldn’t treat him.” — Dr. Katz [07:39]
• Alternative: Focus on controlling risk factors for long-term benefit (“area under the curve” analogy): Start risk reduction early, as lifetime exposure matters.

Notable Quote:
“If this guy has a heart attack, his chance of having a heart attack was 100%—risk calculator be damned.”
— Dr. Katz [06:32]

3. Lifestyle vs. Medical Therapy: Not "Either/Or"

[08:07]–[11:15]

• Dr. Katz advocates for both—“I’m in the both/and camp, not the either/or camp.”
• Encourages lifestyle change in all, but stresses that data on sustained diet/exercise improvement is modest, and delays in medical therapy add up.
• Blood pressure responds better to lifestyle than LDL, which is usually unchanged except in cases of very poor baseline diet or extreme intervention.
• Framing: Lifestyle change is not a reason to delay medications, especially in high-risk patients.

Notable Quote:
“You could eat nothing but steamed broccoli and exercise for a couple of hours a day, and I would probably still want to lower your risk with medications.”
— Dr. Katz [10:42]

4. How to Think About Lipids, Statins, and Advanced Markers

[11:28]–[16:46]

• Statin Conversations: Depends heavily on patient’s prior knowledge/info (especially skepticism from the "wellness internet").
  • First: Listen to the patient’s perspective before recommending.
• Lipoprotein(a) (Lp[a]):
  • Strong marker of genetic risk, checked once.
  • Elevated Lp(a) may tip the scale to more aggressive therapy.
  • Currently, direct treatments are under study.
• Apolipoprotein B (ApoB):
  • Indicates the number of atherogenic particles; sometimes more informative than LDL, esp. in metabolic syndrome.
  • Useful to check once; track ApoB if discordant with LDL.
  • Triglyceride:HDL ratio is a useful clinical clue (“greater than 3:1 makes me suggest insulin resistance”).
  • “If you want to know about cardiovascular disease risk, ApoB tells you how many cars are on the road.” — Dr. Katz [15:02]

Memorable Analogy:
“LDL tells you how many people are traveling up the street... ApoB tells you how many cars are on the road.”
— Dr. Katz [15:04]

5. Statin Management – Initiation, Side Effects, Monitoring

[16:46]–[19:39]

• Side Effects: 8–10% report mild muscle aches, usually reversible.
• Safety Labs: Transaminases may bump mildly; more worrisome only if substantial.
• Glycemic Impact: Potent statins can worsen glucose tolerance very slightly.
• LDL Targets: Aiming for “as low as reasonably achievable” (ALARAA), guided by age, overall risk, imaging (if available).
• Principle: “Lower LDL and lower for longer tends to be linked with lower risk of heart attacks and strokes.” — Dr. Katz [18:56]

6. Aspirin for Primary Prevention

[19:39]–[20:45]

• Simplified: For most, the reduction in heart attack/stroke risk is matched by increase in bleeding—so not broadly recommended.
• Appropriate for primary prevention only in select high-risk individuals who can't get other risk factors controlled.

Notable Quote:
“Aspirin slightly lowers your risk of having a heart attack or stroke, and it increases your risk of clinically significant bleeding by about the same absolute amount.”
— Dr. Katz [19:51]

7. Role of Cardiac Imaging (CAC, CTA, Carotid US)

[20:45]–[23:51]

• When useful:
  • Patients hesitant about medications: “Seeing is believing”—actual images of calcium/asymptomatic plaque are motivating.
  • For more precise risk estimation.
• Limitations:
  • No definitive trials show better outcomes with routine imaging-guided therapy; evidence base is “incomplete.”
  • Calcium score not useful for evaluating chest pain, or in young adults (false reassurance); but any calcification under age 50 is a serious red flag.
  • Imaging changes risk estimates (and clinical decision-making) in ~20–30% of patients.

Notable Quote:
“Patients all know the term hardening of the arteries. You can pull up a CAT scan and show them that there is this bright white substance in your LAD... it really changes how people think about their risk.”
— Dr. Katz [21:46]

8. Multimorbidity & GLP-1 Agonists in Cardiovascular Prevention

[23:51]–[25:47]

• Dr. Katz sees GLP-1 agonists (semaglutide, tirzepatide) as “cardiovascular drugs,” based on evidence (SELECT trial) for risk reduction.
• Cardiologists should feel comfortable prescribing these; may soon be central to primary prevention pharmacotherapy.
  • For multidimensional risk (elevated A1c, BMI, BP, LDL), one medication may address multiple factors.
  • The approach “is not yet standard of care, but might be 10 years from now.”

Notable Quote:
“Maybe instead of putting him on a blood pressure medicine, a lipid-lowering medication, and metformin, you should just put him on tirzepatide... That’s actually going to bring the blood pressure down because of the weight loss.”
— Dr. Katz [25:21]

9. Final Empowerment & Key Message

[26:02]

“I try to empower patients that a lot of their cardiovascular risk is really able to be controlled and that even though this is the most likely reason why human beings... die, it doesn’t have to be. If you’re able to identify and treat the things that cause cardiovascular disease, you can completely change the trajectory of somebody’s lifetime risk.”
— Dr. Katz [26:02]

Additional Memorable Moments

• Traffic metaphor for ApoB — “Are there 10 buses or 1,000 individual cars?” [15:06]
• Host’s reflection: “When you put it like that, it definitely makes a lot of sense...” [08:07]
• Patient-centered perspective: “Is this someone eager to be on medications, or wants to understand their risk?” [03:00]

Segment Timestamps for Key Topics

| Topic | Timestamp | |------------------------------------------------------------|----------------| | Introduction to Prevention | 02:08–05:25 | | Role & Limitations of Risk Calculators | 05:25–08:07 | | Lifestyle vs. Medication – Avoiding False Choices | 08:07–11:15 | | Advanced Lipids (Lp[a], ApoB) & Lipid Panel Analysis | 11:28–16:46 | | Statin Side Effects, Monitoring, and Targets | 16:46–19:39 | | Aspirin for Primary Prevention | 19:39–20:45 | | Role of Cardiac Imaging (CAC, CTA, US) | 20:45–23:51 | | Comorbidities & GLP1 Agonists in CVD Prevention | 23:51–25:47 | | Final Empowerment Message | 26:02 |

Summary: Clinical Pearls

• Act early for high-risk individuals: “Nothing bad has happened yet... we can really do a lot to change his risk.”
• Don’t over-rely on risk calculators; focus on individual risk factor control, using tools like imaging or advanced lipids to clarify uncertainty.
• Lifestyle changes are vital, but not a replacement for medication in high-risk patients—do both.
• ApoB > LDL alone in many cases, especially with metabolic syndrome.
• GLP-1 agonists are game changers: consider their early use for overlapping obesity, diabetes, hypertension, dyslipidemia.
• Empower patients—most CVD risk is modifiable with proactive, multifaceted intervention.

Tone: The conversation is upbeat, direct, and practical, with Dr. Katz blending evidence, vivid analogies, and tactical advice, always centering the patient’s values and risk.

For More: Listen to the full episode for deeper nuance and patient conversations, or review resources from AHA and ACC for evolving guidelines in CVD prevention.